- Charles River Laboratories ( NYSE: CRL ) has sold its Avian Vaccine Services business to private equity firm Arlington Capital Partners.
- The business, now AVS Bio, will operate independently as a standalone platform for Arlington, serving the biologic manufacturing and bioprocessing markets.
- Headquartered in Norwich, Connecticut, AVS Bio provides specific pathogen free eggs and adjacent laboratory products and services that support the development and manufacture of vaccines, therapeutics, and other biologics used for human and animal health. The company has ~250 employees across over 20 facilities located in the U.S. and Europe.
For further details see:
Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital